Jacobio Pharmaceuticals Group Co., Ltd.

SEHK:1167 Rapport sur les actions

Capitalisation boursière : HK$1.5b

Jacobio Pharmaceuticals Group Résultats passés

Passé contrôle des critères 0/6

Jacobio Pharmaceuticals Group has been growing earnings at an average annual rate of 28.7%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been declining at an average rate of 79.9% per year.

Informations clés

28.7%

Taux de croissance des bénéfices

53.7%

Taux de croissance du BPA

Biotechs Croissance de l'industrie11.0%
Taux de croissance des recettes-79.9%
Rendement des fonds propres-39.9%
Marge nette-1,560.9%
Dernière mise à jour des bénéfices30 Jun 2024

Mises à jour récentes des performances passées

Recent updates

Most Shareholders Will Probably Agree With Jacobio Pharmaceuticals Group Co., Ltd.'s (HKG:1167) CEO Compensation

May 31
Most Shareholders Will Probably Agree With Jacobio Pharmaceuticals Group Co., Ltd.'s (HKG:1167) CEO Compensation

Is Jacobio Pharmaceuticals Group (HKG:1167) Using Debt Sensibly?

May 29
Is Jacobio Pharmaceuticals Group (HKG:1167) Using Debt Sensibly?

We're Hopeful That Jacobio Pharmaceuticals Group (HKG:1167) Will Use Its Cash Wisely

May 10
We're Hopeful That Jacobio Pharmaceuticals Group (HKG:1167) Will Use Its Cash Wisely

Time To Worry? Analysts Are Downgrading Their Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Outlook

Aug 26
Time To Worry? Analysts Are Downgrading Their Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Outlook

We're Not Very Worried About Jacobio Pharmaceuticals Group's (HKG:1167) Cash Burn Rate

Jul 29
We're Not Very Worried About Jacobio Pharmaceuticals Group's (HKG:1167) Cash Burn Rate

We Think Jacobio Pharmaceuticals Group (HKG:1167) Can Afford To Drive Business Growth

Apr 29
We Think Jacobio Pharmaceuticals Group (HKG:1167) Can Afford To Drive Business Growth

What Percentage Of Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Shares Do Insiders Own?

Mar 21
What Percentage Of Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Shares Do Insiders Own?

Ventilation des recettes et des dépenses

Comment Jacobio Pharmaceuticals Group gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

SEHK:1167 Recettes, dépenses et bénéfices (CNY Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Jun 2423-36244350
31 Mar 2443-36145361
31 Dec 2364-35947372
30 Sep 2372-38545420
30 Jun 2381-41043468
31 Mar 2389-39143457
31 Dec 2296-37243446
30 Sep 22123-33246391
30 Jun 22150-29249336
31 Mar 22151-29747308
31 Dec 21153-30145281
30 Sep 21348-57052259
30 Jun 21544-83960237
31 Mar 21515-1,17757211
31 Dec 20486-1,51454186
30 Sep 20243-1,29865171
30 Jun 200-1,08277156
31 Mar 200-75374147
31 Dec 190-42571139

Des revenus de qualité: 1167 is currently unprofitable.

Augmentation de la marge bénéficiaire: 1167 is currently unprofitable.


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: 1167 is unprofitable, but has reduced losses over the past 5 years at a rate of 28.7% per year.

Accélération de la croissance: Unable to compare 1167's earnings growth over the past year to its 5-year average as it is currently unprofitable

Bénéfices par rapport au secteur d'activité: 1167 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.5%).


Rendement des fonds propres

ROE élevé: 1167 has a negative Return on Equity (-39.92%), as it is currently unprofitable.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé